These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3077034)

  • 1. Iron-chelating therapy.
    Hershko C; Weatherall DJ
    Crit Rev Clin Lab Sci; 1988; 26(4):303-45. PubMed ID: 3077034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current possibilities in the therapy of iron overload].
    Cermák J
    Vnitr Lek; 1994 Sep; 40(9):605-8. PubMed ID: 7975366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B
    Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron chelation, quo vadis?
    Nick H
    Curr Opin Chem Biol; 2007 Aug; 11(4):419-23. PubMed ID: 17644021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
    Chaston TB; Richardson DR
    Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can iron chelators influence the progression of atherosclerosis?
    Marx JJ; Kartikasari AE; Georgiou NA
    Hemoglobin; 2008; 32(1-2):123-34. PubMed ID: 18274990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Iron chelate treatment of hereditary sideroblastic anemia complicated by hemochromatosis].
    Kremp L; Girot R; Alliot S; Najean Y; Douchain F; Hongre JF
    Arch Fr Pediatr; 1983; 40(6):475-7. PubMed ID: 6625846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of iron overload in the pediatric patient.
    Cohen A
    Hematol Oncol Clin North Am; 1987 Sep; 1(3):521-44. PubMed ID: 3329185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.
    McLaren GD; Muir WA; Kellermeyer RW
    Crit Rev Clin Lab Sci; 1983; 19(3):205-66. PubMed ID: 6373141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
    Weinberg ED
    J Pharm Pharmacol; 2006 May; 58(5):575-84. PubMed ID: 16640825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical applications of iron chelators in photosensitization.
    Juzeniene A; Juzenas P; Iani V; Moan J
    Photochem Photobiol Sci; 2007 Dec; 6(12):1268-74. PubMed ID: 18046481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 15. Iron overload.
    Halliday JW; Powell LW
    Semin Hematol; 1982 Jan; 19(1):42-53. PubMed ID: 6763338
    [No Abstract]   [Full Text] [Related]  

  • 16. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA; Gama S; Gil M; Gano L
    Hemoglobin; 2008; 32(1-2):147-56. PubMed ID: 18274992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of iron-chelating agents in cultured heart muscle cells. Identification of a potential drug for chelation therapy.
    Sciortino CV; Byers BR; Cox P
    J Lab Clin Med; 1980 Dec; 96(6):1081-5. PubMed ID: 7430764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of iron chelators for the treatment of iron overload disease and cancer.
    Kalinowski DS; Richardson DR
    Pharmacol Rev; 2005 Dec; 57(4):547-83. PubMed ID: 16382108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract]   [Full Text] [Related]  

  • 20. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
    Whitnall M; Richardson DR
    Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.